These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 27433025)
1. Hepatoid adenocarcinoma of the lung. Qian GQ; Yin FY; Li GX; Chu JG QJM; 2016 Sep; 109(9):619-20. PubMed ID: 27433025 [No Abstract] [Full Text] [Related]
2. A case of lung adenocarcinoma with multiple cavitary metastases. Murakami S; Manabe S; Yamada K Jpn J Clin Oncol; 2015 May; 45(5):504-5. PubMed ID: 25821230 [No Abstract] [Full Text] [Related]
3. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer. Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985 [No Abstract] [Full Text] [Related]
4. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer. Grossman K; Beasley MB; Braman SS Respir Med; 2016 Oct; 119():175-179. PubMed ID: 27692141 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation. de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158 [No Abstract] [Full Text] [Related]
6. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. Morita S; Yoshida A; Goto A; Ota S; Tsuta K; Yokozawa K; Asamura H; Nakajima J; Takai D; Mori M; Oka T; Tamaru J; Itoyama S; Furuta K; Fukayama M; Tsuda H Am J Surg Pathol; 2013 Jun; 37(6):924-32. PubMed ID: 23629442 [TBL] [Abstract][Full Text] [Related]
7. [Hepatoid Adenocarcinoma of the Lung with High Serum AFP and CEA Values;Report of a Case]. Nakashima K; Okagawa T Kyobu Geka; 2018 Jan; 71(1):76-79. PubMed ID: 29483483 [TBL] [Abstract][Full Text] [Related]
8. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683 [TBL] [Abstract][Full Text] [Related]
9. [Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report]. Manabe M; Mitsuoka S; Umekawa K; Tanaka H; Kimura T; Yoshimura N; Takeda A; Kudoh S; Hirata K Gan To Kagaku Ryoho; 2012 Apr; 39(4):633-5. PubMed ID: 22504691 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story. Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746 [No Abstract] [Full Text] [Related]
14. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681 [TBL] [Abstract][Full Text] [Related]
15. Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R Lung Cancer; 2014 Oct; 86(1):102-4. PubMed ID: 25097032 [TBL] [Abstract][Full Text] [Related]